Chemical formula: C₁₀H₁₆NO+ Molecular mass: 166.24 g/mol PubChem compound: 3202
The safety of edrophonium during pregnancy has not been established. Although the possible hazards to mother and child must be weighed against the potential benefits in every case, experience with edrophonium in pregnant patients with myasthenia gravis has revealed no untoward effect of the drug on the course of pregnancy.
The safety of edrophonium during lactation has not been established. There is no information on the excretion of edrophonium into breast milk. Although only negligible amounts would be expected to be present, due regard should be paid to possible effects on the breast-feeding infant.
None.
These may include nausea and vomiting, increased salivation, diarrhoea and abdominal cramps.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
